Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To find the optimal dose of BAY 1021189 for Phase III that can be given in addition to standard diuretic and comorbidity treatment by characterizing the safety, tolerability, pharmacodynamic effects, and pharmacokinetics, and detecting a significant dose-response relationship in at least one of the two primary endpoints change in NT-proBNP and change of left atrial volume at 12 weeks in patients with worsening chronic heart failure with preserved ejection fraction.
Critère d'inclusion
- Heart failure